- Home
- AARD vs ASPS Comparison
AARD vs ASPS Comparison
Compare AARD & ASPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AARD | ASPS |
|---|---|---|
| Founded | 2017 | 1999 |
| Country | United States | Luxembourg |
| Employees | 40 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Consumer Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 85.7M | 70.7M |
| IPO Year | N/A | 2025 |
Fundamental Metrics
Financial Performance| Metric | AARD | ASPS |
|---|---|---|
| Price | $6.09 | $6.58 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 1 |
| Target Price | ★ $15.29 | $8.00 |
| AVG Volume (30 Days) | ★ 127.6K | 20.4K |
| Earning Date | 05-14-2026 | 04-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 112.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $942,213,000.00 |
| Revenue This Year | N/A | $9.17 |
| Revenue Next Year | N/A | $24.26 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.35 | $0.75 |
| 52 Week High | $17.94 | $15.96 |
Technical Indicators
Market Signals| Indicator | AARD | ASPS |
|---|---|---|
| Relative Strength Index (RSI) | 59.59 | 47.98 |
| Support Level | $4.81 | $6.06 |
| Resistance Level | $11.37 | $7.35 |
| Average True Range (ATR) | 0.40 | 0.45 |
| MACD | 0.10 | -0.01 |
| Stochastic Oscillator | 90.70 | 49.63 |
Price Performance
Historical ComparisonAbout AARD Aardvark Therapeutics Inc.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
About ASPS Altisource Portfolio Solutions S.A.
Altisource Portfolio Solutions SA is an integrated service provider and marketplace for the real estate and mortgage industries. It operates via two reportable segments, namely Servicer and Real Estate, which derive maximum revenue, and Origination. The Servicer and Real Estate segment provides loan servicers and real estate investors with solutions and technologies that span the mortgage and real estate lifecycle. The Origination segment provides originators with solutions and technologies that span the mortgage origination lifecycle. Altisource mainly serves financial institutions, government-sponsored enterprises, and originators in the United States, with the majority of its revenue flowing from field services and mortgage and real estate solutions.